Novartis Ups Ante In Acromegaly Injectables As Oral Contender Emerges
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis gears up to file new injectable pasireotide LAR by the end of 2012 for the niche acromegaly market, ahead of the patent expiration of its blockbuster Sandostatin LAR. But Israeli biotech Chiasma is hoping to deliver an oral option with Octreolin.